

Panacea Biotec

Innovation in support of life

February 14, 2020

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Re.: Press Release – “Unaudited Financial Results for the Quarter & Nine Months ended December 31, 2019”

Dear Sir,

This is in continuation to our letter dated February 14, 2020, along with the copy of Standalone and Consolidated Unaudited Financial Results (Provisional) of the Company for the quarter and nine months ended December 31, 2019, as reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 14, 2020.


Panacea Biotec is now delighted to attach a copy of the Press Release showing the key highlights of the financial results for the quarter and nine months ended December 31, 2019, being released to media, etc. in this regard.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

For Panacea Biotec Limited


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl: as above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Panacea Biotec

Innovation in support of life
New Delhi, February 14, 2020

Press Release

Unaudited Financial Results for the Quarter & Nine months ended December 31, 2019

	Standalone		Consolidated	
	Q3FY2020	9MFY2020	Q3FY2020	9MFY2020
Revenues up by	45%	24%	52%	27%
EBITDA up by	96%	% not measurable	45%	% not measurable

Panacea Biotec Limited (“the Company”), amongst India’s leading Biotechnology companies announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2019. These results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on February 14, 2020.


Key highlights of standalone financial results for the quarter ended December 31, 2019 (Q3FY2020 vs Q3FY2019) are as under:

- Pharmaceutical Business revenues grew by 29% to Rs. 1,051 mn during Q3FY2020.
- Vaccine Business revenues grew by 90% to Rs. 555 mn during Q3FY2020.
- Overall revenues grew by 45% to Rs. 1,606 mn during Q3FY2020.
- EBITDA grew by 96% to Rs. 340 mn during Q3FY2020.

Key highlights of Standalone financial results for none months ended December 31, 2019 (9MFY2020 vs 9MFY2019) are as under:

- Pharma Business revenues grew by 17% to Rs. 3,003 mn during 9MFY2020.
- Vaccine Business revenues grew by 51% to Rs. 1,013 mn during 9MFY2020.
- Overall revenues grew by 24% to Rs. 4,016 mn during 9MFY2020.
- EBITDA of Rs. 756 mn during 9MFY2020 as against loss of Rs. 113 mn during 9MFY2019.

Explaining the results, Dr. Rajesh Jain, Managing Director of the Company said, “The Company has continued to register impressive standalone financial performance during the quarter ended December 31, 2019 with 45% topline growth and 96% EBITDA growth. Our sharpened focus on operational and financial efficiencies will continue with equal emphasis on opening new International markets and accelerating late stage innovative products for sustainable growth.”



Panacea Biotec Pharma Limited

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.

Ph.:+91-41578000; e-mail: pharma@panaceabiotec.com

Panacea Biotec

Innovation in support of life

Key updates:

- **Long Term Awards:** received from PAHO & UNICEF for 25.98 mn doses of Easyfive-TT worth US\$ 25.98 mn (~Rs. 173 Crores) for CY2020-2022.*
- **Key Managerial appointment during Q3FY2020:**
 - Mr. Susheel Umesh, having over 27 years of experience, joined PBL on November 18, 2019 as Chief Executive – Domestic Pharmaceutical Formulations business.
- **New Product Launches:** Panacea Biotec launched Branded generic version of Vildagliptin and combinations of Vildagliptin + Metformin under the trademark of VILACT and VILACT-M respectively on December 10, 2019.
- **Slump sale of Pharma Business:** The process of transfer of pharmaceutical business transfer from the Company to its wholly owned subsidiary company Panacea Biotec Pharma Ltd. under the Business Transfer Agreement has been completed with effect from February 1, 2020.
- **Demerger of Real Estate Undertaking:** The shareholders of the Company have approved the demerger in the EGM held on January 28, 2020. The Company has also received approval of the unsecured creditors in their meeting held on January 28, 2020.


*UN Agencies awards of number of estimated doses is not a commitment or guarantee on the part of UN Agencies to purchase any products.

About Panacea Biotec

Panacea Biotec is amongst India's leading **biotechnology company** with deep Research, Development, Manufacturing and Marketing capabilities. Awarded the **Thomson Reuters "Top 50 Innovator of the Year award"**.

Panacea Biotec has 5 SBUs focusing on organ transplant, diabetes, gastroenterology, osteoporosis, osteoarthritis, oncology and pediatric vaccines in India. Panacea Biotec has been ranked amongst the top 12 pharmaceutical companies in its represented market in India and amongst top 60 pharmaceutical Companies in India (AIOCD December 2019). The Company has commercialized its products in over 30 countries including USA, Germany, Russian Federation etc. through a combination of strategic collaborations and direct presence in select geographies.

Panacea Biotec's research program focuses on developing pharmaceutical medicines for chronic diseases such as Diabetes, Organ transplantation, Osteoporosis, Pain management, Oncology and Gastroenterology and Vaccines for common morbid conditions such as Pneumonia, Dengue,



Panacea Biotec Pharma Limited

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.

Ph.:+91-41578000; e-mail: pharma@panaceabiotec.com




Panacea Biotec

Innovation in support of life

Hepatitis B, Polio, Diphtheria, Pertussis and Tetanus among others. The Company has research programs focused on developing **New Chemical Entities (NCE)**, **New Biological Entities (NBE)** and **Novel Drug Delivery Systems (NDDS)** platform technologies such as nanoparticle, liposomal and gastro-retentive delivery systems among others.

For more information, please contact:

For Investors	For Media
Mr. Devender Gupta Chief Financial Officer and Head Information Technology Tel: + 91-11-41679000 Ext. 1225, 41578011 Mobile: +91 98109 04102 Email: devendergupta@panaceabiotec.com	Mr. P. D. Karan Vice President - Corporate Communication & Business Development Tel: + 91 11 41679000 Extn. 1406, 41578080 Mobile: + 91 9312693040, + 91 9810500539 Email: pdkaran@panaceabiotec.com

Panacea Biotec Pharma Limited

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.

Ph.:+91-41578000; e-mail: pharma@panaceabiotec.com